Italfarmaco Group Announces Positive Topline Data from Phase 3 Trial Showing Beneficial Effect of Givinostat in Patients with Duchenne Muscular Dystrophy
— Study meets primary endpoint with secondary and exploratory endpoints showing consistency with primary endpoint — — Data reinforces previously observed safety profile for Givinostat; treatment in boys with DMD continues to show a good tolerability profile — — The company is planning to discuss the potential for marketing application submission with regulatory authorities for … [Read more…]
